Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MannKind and Pfizer have announced that MannKind will transition certain Exubera patients with a continuing need for inhaled insulin to MannKind's inhaled insulin product, Technosphere Insulin, an investigational product that has recently completed Phase III clinical trials.
Subscribe to our email newsletter
Pfizer has previously announced that it would stop marketing Exubera inhalation powder because it did not meet customers’ needs or Pfizer’s financial expectations. Since that time, Exubera patients have been transitioning to other diabetes therapies, although there remains a small number of patients with a continuing medical need for inhaled insulin.
Pfizer began discussions with MannKind to give these patients access to Technosphere Insulin. Pfizer will reimburse some of MannKind’s costs relating to the transition of patients.
Hakan Edstrom, president and COO of MannKind, said: “We’re pleased to work with Pfizer as we transition these patients and to help them manage their diabetes.”